Drug Profile
Propentofylline
Alternative Names: Albert 285; Hextol; HWA 285; ViviqLatest Information Update: 26 Aug 2004
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Antineoplastics; Nootropics; Small molecules; Xanthines
- Mechanism of Action Adenosine A1 receptor modulators; Adenosine A2 receptor modulators; Astrocyte modulators; Glial cell inhibitors; Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Cerebrovascular disorders
- Discontinued Alzheimer's disease; Stroke; Vascular dementia
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 06 Mar 2000 Discontinued-III for Alzheimer's disease in USA (Unknown route)